Compare · CONX vs IBER
CONX vs IBER
Side-by-side comparison of CONX Corp. (CONX) and Ibere Pharmaceuticals (IBER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CONX and IBER operate in Blank Checks (Finance), so they compete in similar markets.
- CONX is the larger of the two at $919.0M, about 5.5x IBER ($167.2M).
CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including the wireless communications industry. The company was incorporated in 2020 and is based in Littleton, Colorado.
Ibere Pharmaceuticals
Ibere Pharmaceuticals focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
Latest CONX
- SEC Form 10-Q filed by CONX Corp.
- SEC Form SC 13D filed by CONX Corp.
- SEC Form SC 13D filed by CONX Corp.
- CONX Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Ergen Charles W converted options into 18,750,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Gst-Exempt Ranch Legacy Trust
- CONX Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- CONX Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
- CONX Corp. Announces Closing of Initial Business Combination
- SEC Form SC 13G/A filed by CONX Corp. (Amendment)
Latest IBER
- SEC Form 15-12G filed by Ibere Pharmaceuticals
- SEC Form 25-NSE filed by Ibere Pharmaceuticals
- Ibere Pharmaceuticals filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Ibere Pharmaceuticals Will Redeem All Outstanding Ordinary Shares Included In Units Issued In IPO Effective As Of Close Of Business On March 2; Per-Share Redemption Price For Public Shares Will Be ~$10.17; Expects That NYSE Will File Form 25 To Delist Co
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G filed by Ibere Pharmaceuticals
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form SC 13G/A filed by Ibere Pharmaceuticals (Amendment)
- SEC Form 10-Q filed by Ibere Pharmaceuticals